Evidence map›Paper›PMID 27556046›Full record

ArticleBioMed research international2016

Sodium Tanshinone IIA Sulfonate Attenuates Scopolamine-Induced Cognitive Dysfunctions via Improving Cholinergic System.

Qing-Qing Xu, Yi-Jun Xu, Cong Yang, Ying Tang, Lin Li, Hao-Bin Cai, Bo-Nan Hou, Hui-Fang Chen, Qi Wang, Xu-Guang Shi and 1 more

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Effects of long-termSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Neural regeneration research · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Qing-Qing XuInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.ORCID 0000-0002-3920-3556
Yi-Jun XuInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Cong YangInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Ying TangThe First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.ORCID 0000-0001-5666-8139
Lin LiInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Hao-Bin CaiInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.ORCID 0000-0001-6917-1850
Bo-Nan HouInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Hui-Fang ChenInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Qi WangInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Xu-Guang ShiSchool of Chinese Materia Medica, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.ORCID 0000-0003-2437-6400
Shi-Jie ZhangInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.ORCID 0000-0001-5399-7260
Guangzhou University of Chinese Medicine · CNFirst Affiliated Hospital of Guangzhou University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sodium Tanshinone IIA sulfonate (STS) is a derivative of Tanshinone IIA (Tan IIA). Tan IIA has been reported to possess neuroprotective effects against Alzheimer's disease (AD). However, whether STS possesses effect on AD remains unclear. This study aims to estimate whether STS could protect against scopolamine- (SCOP-) induced learning and memory deficit in Kunming mice. Morris water maze results showed that oral administration of STS (10 mg/kg and 20 mg/kg) and Donepezil shortened escape latency, increased crossing times of the original position of the platform, and increased the time spent in the target quadrant. STS decreased the activity of acetylcholinesterase (AChE) and increased the activity of choline acetyltransferase (ChAT) in the hippocampus and cortex of SCOP-treated mice. Oxidative stress results showed that STS increased the activity of superoxide dismutase (SOD) and decreased the levels of malondialdehyde (MDA) and reactive oxygen species (ROS) in hippocampus and cortex. In addition, western blot was carried out to detect the expression of apoptosis related proteins (Bcl-2, Bax, and Caspase-3). STS upregulated the protein expression of Bcl-2 and downregulated the proteins expression of Bax and Caspase-3. These results indicated that STS might become a promising therapeutic candidate for attenuating AD-like pathological dysfunction.

Indexed as

Alzheimer DiseaseAnimalsCognitive DysfunctionHippocampusHumansLearning DisabilitiesMaze LearningMiceNon-Neuronal Cholinergic SystemOxidative StressPhenanthrenesScopolaminePhenanthrenesScopolaminetanshinone II A sodium sulfonate

Identifiers

PMID27556046
PMCPMC4983342
OpenAlexW2479428629

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.